Fig. 5From: The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trialsForest plots of subgroup analysis of the OS for additional anti-EGFR target agents on mCRC a RAS/KRAS wild-type patients (p = 0.031). b KRAS mutant patients (p = 0.250)Back to article page